MUSC Hollings Cancer Center is one of fewer than 70 cancer centers in the nation - and the only one in South Carolina - to receive a designation from the National Cancer Institute (NCI). Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells . Hollings is enrolling patients in a national clinical trial to help to determine the best, most cost-effective approach for treating prostate cancer through radiation therapy. Call 843-792-8300 and speak to a research professional about other study opportunities available at MUSC. Search for MUSC Hollings Cancer Center Clinical Trials Search for all South Carolina Clinical Trials Information on ResearchMatch: People who would like to participate in research studies now can connect with researchers throughout the country by joining a first-of-its-kind, on-line "matching system." Clinical trials at MUSC Hollings Cancer Center are research studies exploring promising new approaches for cancer prevention, diagnosis, and treatment. Study Objectives: This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. The MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Clinical Trials. CLINICAL TRIALS . Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. The center has an annual research funding portfolio of over $44 million and offers more than 200 clinical trials. The MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Our team of more than 60 super-specialists - each concentrating on a specific discipline of cancer treatment and care - works with individual patients to develop customized treatment programs that target a . The MUSC Hollings Cancer Center Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina. Study Title: A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer. Study Objectives: This study is a large . NCT Number: NCT03646123. The center's mission is to reduce the cancer burden in South Carolina and beyond through high-quality cancer care, clinical research, professional education, and community outreach programs. Hollings has a robust interdisciplinary research base that includes more than 110 physicians and basic and population scientists from five MUSC colleges . With our ability to offer clinical trials and therapies not available elsewhere in South Carolina, including . Clinical Research Trials. The trial, which utilizes a medicine called AG-120, sold under the brand name Tibsovo, gives patients with few other treatment options new hope for a better life and possible remission. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. A clinical trial at MUSC Hollings Cancer Center is being hailed as a game changer by doctors for certain leukemia and myelodysplastic syndrome (MDS) patients. Sponsor: Regeneron Sponsor Study ID: R3767-ONC-1613 Study Title: A Phase 1, Open-Label, Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies The study will enroll approximately 140 patients. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in these heavily pretreated children and young adults. Sponsor Study ID: SGN35-027 Study Title: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects NCT Number: NCT03646123 Phase: II Protocol Type: Treatment Age Group: Adult and Children Disease Sites: Hodgkin's Lymphoma MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The purpose of the CTO is to provide an effective and efficient infrastructure to support Hollings investigators in developing, implementing, and reporting on all . Through our participation in research trials with the National Cancer Institute and our partnership with the Hollings Cancer Center Clinical Trials Network at the Medical University of South Carolina, our patients have access to the most advanced technologies and treatments available while remaining close to home. Study Title: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects. Hollings Cancer Center Trials - Cancer research clinical trials at MUSC. The purpose of the CTO is to provide an effective and efficient infrastructure to support Hollings investigators in developing, implementing, and reporting on all . With our ability to offer clinical trials and therapies not available elsewhere in South Carolina, including . Hollings has a robust interdisciplinary research base that includes more than 110 physicians and basic and population scientists from five MUSC colleges .
Mobile Homes For Sale In East Hartford Connecticut, Example Of Motivational Speech About Life, Dak Prescott Contract Jordan, Sermon On Romans 1:16-25, Home Construction Companies Near Me, Cute, Small Gifts For Boyfriend, Peter Beardsley Wife Eggs, Green Mountain Coffee Caramel Vanilla Cream, Clippers Won't Cut Poodle Hair, Healthy Sweet Potato Pudding, Apartments For Rent In Alabama With Utilities Included, 2021 Lamborghini Urus, Ray-ban Sale Wayfarer,